Recombinant live vaccine candidates against tuberculosis

Current Opinion in Biotechnology

Volumn 23, Issue 6, 2012, Pages 900-907

  Kaufmann, Stefan HE ^a   Gengenbacher, Martin ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; IMMUNE RESPONSE; LONG LASTING; MOLECULAR BASIS;

GENETIC ENGINEERING; HEALTH RISKS; TUBES (COMPONENTS);

VACCINES;

AERAS 422; BCG VACCINE; LIVE VACCINE; MTBVAC 01; PERFORIN; RBCG 30; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VPM 1002;

BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MTB GENE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; STRAIN DIFFERENCE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION;

ANIMALS; BCG VACCINE; HUMANS; MYCOBACTERIUM BOVIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS);

EID: 84869887217     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2012.03.007     Document Type: Review

References (64)

1. Calmette A., Guérin C., Boquet A., Négre L. La vaccination préventive contre la tuberculose par le " BCG" 1927, Paris, Masson.
2. Talbot E.A., Perkins M.D., Silva S.F., Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 1997, 24:1139-1146.
3. Kaufmann S.H.E., Hussey G., Lambert P.H. New vaccines for tuberculosis. Lancet 2010, 375:85-94.
4. Lawn S.D., Zumla A.I. Tuberculosis. Lancet 2011, 378:57-72.
5. WHO: Global Tuberculosis Control 2011. Geneva, World Health Organization; 2011.
6. Gandhi N.R., Nunn P., Dheda K., Schaaf H.S., Zignol M., van S.D., Jensen P., Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
7. Udwadia Z.F., Amale R.A., Ajbani K.K., Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012, 54:579-581.
8. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., Dos Santos S., Duthoy S., Lacroix C., Garcia-Pelayo C., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007, 104:5596-5601.
9. Brodin P., Majlessi L., Marsollier L., de Jonge M.I., Bottai D., Demangel C., Hinds J., Neyrolles O., Butcher P.D., Leclerc C., et al. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect Immun 2006, 74:88-98.
10. Simeone R., Bottai D., Brosch R. ESX/type VII secretion systems and their role in host-pathogen interaction. Curr Opin Microbiol 2009, 12:4-10.
11. Majlessi L., Brodin P., Brosch R., Rojas M.J., Khun H., Huerre M., Cole S.T., Leclerc C. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J Immunol 2005, 174:3570-3579.
12. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., Griffiths K.E., Marchal G., Leclerc C., Cole S.T. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003, 9:533-539.
13. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine 2009, 27:441-445.
14. Keyser A., Troudt J.M., Taylor J.L., Izzo A.A. BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity. Vaccine 2011, 29:9308-9315.
15. Smith D.W. Protective Effect of BCG in Experimental Tuberculosis 1985, Karger, Basel.
16. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
17. van der Wel N., Hava D., Houben D., Fluitsma D., van Z.M., Pierson J., Brenner M., Peters P.J. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007, 129:1287-1298.
18. Gengenbacher M, Kaufmann SHE: Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012, doi:10.1111/j.1574-6976.2012.00331.x.
19. Walker K.B., Brennan M.J., Ho M.M., Eskola J., Thiry G., Sadoff J., Dobbelaer R., Grode L., Liu M.A., Fruth U., Lambert P.H. The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 2010, 28:2259-2270.
20. Ford C.B., Lin P.L., Chase M.R., Shah R.R., Iartchouk O., Galagan J., Mohaideen N., Ioerger T.R., Sacchettini J.C., Lipsitch M., et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011, 43:482-486.
21. Kaufmann S.H. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011, 11:633-640.
22. Gaillard J.L., Berche P., Mounier J., Richard S., Sansonetti P. In vitro model of penetration and intracellular growth of Listeria monocytogenes in the human enterocyte-like cell line Caco-2. Infect Immun 1987, 55:2822-2829.
23. Geoffroy C., Gaillard J.L., Alouf J.E., Berche P. Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes. Infect Immun 1987, 55:1641-1646.
24. Bavdek A., Kostanjsek R., Antonini V., Lakey J.H., Dalla S.M., Gilbert R.J., Anderluh G. pH dependence of listeriolysin O aggregation and pore-forming ability. FEBS J 2012, 279:126-141.
25. Decatur A.L., Portnoy D.A. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000, 290:992-995.
26. Schnupf P., Portnoy D.A., Decatur A.L. Phosphorylation, ubiquitination and degradation of listeriolysin O in mammalian cells: role of the PEST-like sequence. Cell Microbiol 2006, 8:353-364.
27. Hess J., Miko D., Catic A., Lehmensiek V., Russell D.G., Kaufmann S.H.E. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 1998, 95:5299-5304.
28. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., Mann P., Goosmann C., Bandermann S., Smith D., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
29. Desel C., Dorhoi A., Bandermann S., Grode L., Eisele B., Kaufmann S.H. Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 204:1573-1584.
30. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97:13853-13858.
31. Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003, 71:1672-1679.
32. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., Weichold F., Geiter L., Sadoff J.C., Horwitz M.A. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198:1491-1501.
33. Tullius M.V., Harth G., Maslesa-Galic S., Dillon B.J., Horwitz M.A. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 2008, 76:5200-5214.
34. Kupferschmidt K. Infectious disease. Taking a new shot at a TB vaccine. Science 2011, 334:1488-1490.
35. Sun R., Skeiky Y.A., Izzo A., Dheenadhayalan V., Imam Z., Penn E., Stagliano K., Haddock S., Mueller S., Fulkerson J., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27:4412-4423.
36. Schuck S.D., Mueller H., Kunitz F., Neher A., Hoffmann H., Franken K.L., Repsilber D., Ottenhoff T.H., Kaufmann S.H., Jacobsen M. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS ONE 2009, 4:e5590.
37. Tweten R.K. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 2005, 73:6199-6209.
38. Perez E., Samper S., Bordas Y., Guilhot C., Gicquel B., Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001, 41:179-187.
39. Frigui W., Bottai D., Majlessi L., Monot M., Josselin E., Brodin P., Garnier T., Gicquel B., Martin C., Leclerc C., et al. Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog 2008, 4:e33.
40. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., Soto C.Y., Clark S.O., Hatch G.J., Aguilar D., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24:3408-3419.
41. Infante E., Aguilar L.D., Gicquel B., Pando R.H. Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant. Clin Exp Immunol 2005, 141:21-28.
42. Ferrer N.L., Gomez A.B., Soto C.Y., Neyrolles O., Gicquel B., Garcia-Del P.F., Martin C. Intracellular replication of attenuated Mycobacterium tuberculosis phoP mutant in the absence of host cell cytotoxicity. Microbes Infect 2009, 11:115-122.
43. Cardona P.J., Asensio J.G., Arbues A., Otal I., Lafoz C., Gil O., Caceres N., Ausina V., Gicquel B., Martin C. Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. Vaccine 2009, 27:2499-2505.
44. Master S.S., Rampini S.K., Davis A.S., Keller C., Ehlers S., Springer B., Timmins G.S., Sander P., Deretic V. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe 2008, 3:224-232.
45. Johansen P., Fettelschoss A., Amstutz B., Selchow P., Waeckerle-Men Y., Keller P., Deretic V., Held L., Kundig T.M., Bottger E.C., Sander P. Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens. Clin Vaccine Immunol 2011, 18:907-913.
46. Sambandamurthy V.K., Derrick S.C., Hsu T., Chen B., Larsen M.H., Jalapathy K.V., Chen M., Kim J., Porcelli S.A., Chan J., et al. Mycobacterium tuberculosis ΔRD1 ΔpanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 2006, 24:6309-6320.
47. Sambandamurthy V.K., Jacobs W.R. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 2005, 7:955-961.
48. Sampson S.L., Dascher C.C., Sambandamurthy V.K., Russell R.G., Jacobs W.R., Bloom B.R., Hondalus M.K. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 2004, 72:3031-3037.
49. Dick T., Manjunatha U., Kappes B., Gengenbacher M. Vitamin B6 biosynthesis is essential for survival and virulence of Mycobacterium tuberculosis. Mol Microbiol 2010, 78:980-988.
50. Gey van Pittius N.C., Gamieldien J., Hide W., Brown G.D., Siezen R.J., Beyers A.D. The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol 2001, 2. RESEARCH0044.
51. Stinear T.P., Seemann T., Harrison P.F., Jenkin G.A., Davies J.K., Johnson P.D., Abdellah Z., Arrowsmith C., Chillingworth T., Churcher C., et al. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res 2008, 18:729-741.
52. Sweeney K.A., Dao D.N., Goldberg M.F., Hsu T., Venkataswamy M.M., Henao-Tamayo M., Ordway D., Sellers R.S., Jain P., Chen B., et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011, 17:1261-1268.
53. Jacobsen M., Repsilber D., Gutschmidt A., Neher A., Feldmann K., Mollenkopf H.J., Ziegler A., Kaufmann S.H. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 2007, 85:613-621.
54. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., Wilkinson K.A., Banchereau R., Skinner J., Wilkinson R.J., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
55. Harries A.D., Zachariah R., Corbett E.L., Lawn S.D., Santos-Filho E.T., Chimzizi R., Harrington M., Maher D., Williams B.G., De Cock K.M. The HIV-associated tuberculosis epidemic-when will we act?. Lancet 2010, 375:1906-1919.
56. Fennelly G.J., Flynn J.L., ter M.V., Liebert U.G., Bloom B.R. Recombinant bacille Calmette-Guerin priming against measles. J Infect Dis 1995, 172:698-705.
57. Govan V.A., Christensen N.D., Berkower C., Jacobs W.R., Williamson A.L. Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 2006, 24:2087-2093.
58. Langermann S., Palaszynski S.R., Burlein J.E., Koenig S., Hanson M.S., Briles D.E., Stover C.K. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J Exp Med 1994, 180:2277-2286.
59. Edelman R., Palmer K., Russ K.G., Secrest H.P., Becker J.A., Bodison S.A., Perry J.G., Sills A.R., Barbour A.G., Luke C.J., et al. Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine 1999, 17:904-914.
60. Stover C.K., Bansal G.P., Hanson M.S., Burlein J.E., Palaszynski S.R., Young J.F., Koenig S., Young D.B., Sadziene A., Barbour A.G. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 1993, 178:197-209.
61. Chapman R., Chege G., Shephard E., Stutz H., Williamson A.L. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res 2010, 8:282-298.
62. Matsumoto S., Yukitake H., Kanbara H., Yamada T. Recombinant Mycobacterium bovis bacillus Calmette-Guerin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. J Exp Med 1998, 188:845-854.
63. Arama C., Waseem S., Fernandez C., Assefaw-Redda Y., You L., Rodriguez A., Radosevic K., Goudsmit J., Kaufmann S.H., Reece S.T., Troye-Blomberg M. A recombinant Bacille Calmette-Guerin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice. Vaccine 2011, 10.1016/j.vaccine.2011.09.054.
64. Kaufmann S.H.E., Winau F. From bacteriology to immunology: the dualism of specificity. Nat Immunol 2005, 6:1063-1066.